Back to results
US 6,146,633 AGranted
Method for treatment of antigenically modified polypeptides
AssigneeThe Ohio State University
InventorVernon C. Stevens
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeThe Ohio State University
InventorVernon C. Stevens
Estimating the term…
Endogenous and exogenous proteins, and fragments thereof, are chemically modified outside the body of an animal so that when injected into the animal they produce more antibodies against the unmodified protein than would injection of the unmodified protein or fragment alone. The chemical modification may be accomplished by attaching the proteins or fragments to carriers such as, for example, bacterial toxoids. The chemical modification can also be accomplished by polymerization of protein fragments. Proteins which can be modified include Follicle Stimulating Hormone and Human Chorionic Gonadotropin. The modified polypeptide may be administered to animals for the purpose of contraception, abortion or treatment of hormone-related disease states and disease disorders, treatment of hormone-associated carcinomas, and to boost the animals' resistance to exogenous proteins, for example viral proteins.
Polyclonal antibodies reactive with a reproductive protein hormone endogenous and non-immunogenic to a selected mammalian species, said antibodies being non-immunogenic to and produced in a mammal of said selected species by administering to said mammal, an effective amount of a polypeptide determinant of said reproductive hormone conjugated to a carrier biologically foreign to said selected mammalian species, said polypeptide determinant selected from a group consisting of said reproductive protein hormone endogenous to said selected mammalian species, a fragment of said protein hormone, and a synthetic polypeptide including at least one epitope of said endogenous protein hormone;
Polyclonal antibodies formed in a selected mammal in response to administration of a polypeptide derived from said selected mammal which is substantially non-immunogenic to said selected mammal which has been modified outside the body of said mammal prior to said administration, said antibodies being reactive with a reproductive protein hormone endogenous and non-immunogenic to said selected mammal.
Dependencies are inferred from the claim text.